Understanding the role of MRAs in management of heart failure with Cardiologist Dr Rajeev Agarwala
|
Overview
Designated as an emerging epidemic in 1997, Heart failure is still a major clinical and public health concern. Many medicines previously used have gone into disrepute, while many others have been found to be useful.
Recently, 2021 update on the 2017 ACC expert consensus decision pathway has upgraded mineralocorticoid receptor antagonist (MRA) as a class 1 indication for the treatment of Heart failure with reduced ejection fraction.
Dr Rajeev Agarwala , an eminent cardiologist explains the role of MRAs in the management of heart failure.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Rajeev Agarwala, MBBS( Hons), MD(Med), DM (Cardio) is a Consultant Cardiologist in Meerut with over 25 years of experience. He chairs the Dept. of Cardiology at Jaswant Rai Speciality Hospital Meerut. Dr Agarwala was awarded Amar Ujala National Excellence Award for Life Time Achievement in 2017.
